Terns Pharmaceuticals, Inc.

Equities

TERN

US8808811074

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
4.91 ^USD	+5.82%		+7.68%	-24.35%

Apr. 10	Terns Pharmaceuticals, Inc. Appoints Melita Sun Jung as Chief Business Officer	CI
Mar. 27	UBS Trims Terns Pharmaceuticals Price Target to $18 From $19, Maintains Buy Rating	MT

Terns Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 14, 2024 at 04:16 pm EDT

Terns Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 90.21 million compared to USD 60.35 million a year ago. Basic loss per share from continuing operations was USD 1.27 compared to USD 1.67 a year ago.

Latest news about Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Appoints Melita Sun Jung as Chief Business Officer	Apr. 10	CI
UBS Trims Terns Pharmaceuticals Price Target to $18 From $19, Maintains Buy Rating	Mar. 27	MT
North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
JMP Securities Cuts Terns Pharmaceuticals Price Target to $15 From $17, Maintains Market Outperform Rating	Mar. 18	MT
BMO Capital Adjusts Price Target on Terns Pharmaceuticals to $19 From $18, Maintains Outperform Rating	Mar. 15	MT
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14	CI
Terns Pharmaceuticals Gets Orphan Drug Label for Chronic Myeloid Leukemia Treatment Candidate	Mar. 11	MT
Terns Pharmaceuticals, Inc. Appoints Amy Burroughs as Chief Executive Officer	Feb. 07	CI
Terns Pharmaceuticals, Inc. Appoints Amy Burroughs as Member of Board of Directors	Feb. 07	CI
Jefferies Adjusts Terns Pharmaceuticals Price Target to $22 From $18, Maintains Buy Rating	Jan. 18	MT
HC Wainwright Adjusts Price Target on Terns Pharmaceuticals to $5.50 From $8, Maintains Neutral Rating	Jan. 10	MT
Mizuho Adjusts Price Target on Terns Pharmaceuticals to $10 From $17, Maintains Buy Rating	Nov. 27	MT
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Terns Pharmaceuticals, Inc. Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity	Nov. 02	CI
Terns Pharmaceuticals, Inc.(NasdaqGS:TERN) added to S&P Global BMI Index	23-09-18	CI
HC Wainwright Adjusts Price Target on Terns Pharmaceuticals to $8 From $11, Keeps Neutral Rating	23-08-10	MT
Mizuho Ups Price Target on Terns Pharmaceuticals to $17 From $16, Keeps Buy Rating	23-08-09	MT
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Terns Pharmaceuticals, Inc. Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR-ß Agonist TERN-501 in NASH	23-08-08	CI
Terns Pharmaceuticals Chief Executive Senthil Sundaram Resigns Due to Health Reasons	23-08-04	MT
Terns Pharmaceuticals, Inc. Announces Leadership Transition	23-08-03	CI
Terns Pharmaceuticals Announces Leadership Transition	23-08-03	CI
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday	23-06-27	MT
Terns Pharmaceuticals Says New Preclinical Data of TERN-601 Shows Improved Glucose Tolerance in Mouse Model	23-06-26	MT

Chart Terns Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.91 USD

Average target price

14.21 USD

Spread / Average Target

+189.50%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TERNS PHARMACEUTICALS, INC.	-24.35%	318M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research